MCID: THY023
MIFTS: 65

Thymoma

Categories: Rare diseases, Genetic diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Thymoma

Summaries for Thymoma

Disease Ontology : 12 A thymus cancer that derives from epithelial cells located in the thymus. The tumor cells in a thymoma look similar to the normal cells of the thymus, grow slowly, and rarely spread beyond the thymus.

MalaCards based summary : Thymoma, also known as thymus neoplasms, is related to spindle cell thymoma and epithelial malignant thymoma, and has symptoms including nephrotic syndrome, xerostomia and ptosis. An important gene associated with Thymoma is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways/superpathways are Developmental Biology and Class I MHC mediated antigen processing and presentation. The drugs Azathioprine and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include the thymus, thymus and lung, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 72 A thymoma is a tumor originating from the epithelial cells of the thymus that may be benign or... more...

Related Diseases for Thymoma

Diseases in the Thymoma family:

Thymoma, Familial Invasive Malignant Thymoma
Type C Thymoma Malignant Type Ab Thymoma
Malignant Type a Thymoma Thymoma Type a
Thymoma Type B Thymoma Type Ab

Diseases related to Thymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 283)
# Related Disease Score Top Affiliating Genes
1 spindle cell thymoma 33.5 CD5 LCK
2 epithelial malignant thymoma 33.5 CD5 LCK
3 dendritic cell thymoma 33.4 CD5 LCK TTN
4 mixed type thymoma 33.0 CD5 KIT
5 cortical thymoma 32.9 CD2 TTN
6 thymic epithelial tumor 32.1 CD5 KIT
7 myasthenia gravis 31.8 AIRE CTLA4 IL2 RYR1 TTN
8 thymus cancer 31.6 CD5 DNTT DPYSL5 KIT NKX2-1
9 autoimmune addison disease 29.8 AIRE CTLA4
10 lymphoblastic lymphoma 29.6 CD5 DNTT PTPRC
11 alopecia areata 29.6 AIRE CTLA4 IL2
12 pemphigus foliaceus 29.5 CTLA4 EVPL PPL
13 lymphoma, non-hodgkin, familial 29.1 CD5 DNTT IL2 PTPRC
14 follicular dendritic cell sarcoma 29.0 EVPL KIT PPL
15 thymoma, familial 12.4
16 immunodeficiency with thymoma 12.2
17 invasive malignant thymoma 12.1
18 type c thymoma 12.0
19 encapsulated thymoma 12.0
20 combined thymoma 12.0
21 thymoma type b 12.0
22 predominantly cortical thymoma 11.9
23 malignant type ab thymoma 11.9
24 noninvasive malignant thymoma 11.9
25 malignant type a thymoma 11.9
26 thymoma type a 11.8
27 thymoma type ab 11.8
28 good syndrome 11.8
29 thymoma, childhood 11.8
30 pure red-cell aplasia 11.3
31 acquired pure red cell aplasia 11.2
32 limbic encephalitis with lgi1 antibodies 10.9
33 myasthenia gravis congenital 10.6
34 hemangioma of lung 10.4 AKT1 NKX2-1
35 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.3
36 maxillary sinus adenoid cystic carcinoma 10.3 IL2 KIT
37 lobomycosis 10.2 AIRE CD2
38 type 1 diabetes mellitus 17 10.2 AIRE CTLA4
39 pemphigus 10.2
40 cervicitis 10.2
41 mediastinitis 10.2
42 encephalitis 10.1
43 autoimmune disease of endocrine system 10.1 AIRE CTLA4 IL2
44 hypersensitivity reaction disease 10.1 AIRE CTLA4 IL2
45 lymphoma 10.1
46 myocarditis 10.0
47 limbic encephalitis 10.0
48 sm-ahnmd 10.0 CD2 KIT
49 small cell carcinoma 10.0 KIT NKX2-1 PTPRC
50 thyroiditis 10.0

Graphical network of the top 20 diseases related to Thymoma:



Diseases related to Thymoma

Symptoms & Phenotypes for Thymoma

Human phenotypes related to Thymoma:

31 (show all 29)
# Description HPO Frequency HPO Source Accession
1 nephrotic syndrome 31 occasional (7.5%) HP:0000100
2 xerostomia 31 occasional (7.5%) HP:0000217
3 ptosis 31 frequent (33%) HP:0000508
4 diplopia 31 frequent (33%) HP:0000651
5 skin rash 31 occasional (7.5%) HP:0000988
6 keratoconjunctivitis sicca 31 occasional (7.5%) HP:0001097
7 arthritis 31 occasional (7.5%) HP:0001369
8 limitation of joint mobility 31 occasional (7.5%) HP:0001376
9 alopecia 31 occasional (7.5%) HP:0001596
10 pericarditis 31 occasional (7.5%) HP:0001701
11 pancytopenia 31 occasional (7.5%) HP:0001876
12 hemolytic anemia 31 occasional (7.5%) HP:0001878
13 dysphagia 31 frequent (33%) HP:0002015
14 dyspnea 31 frequent (33%) HP:0002094
15 abnormality of the pleura 31 occasional (7.5%) HP:0002103
16 abnormality of the peritoneum 31 occasional (7.5%) HP:0002585
17 lymphadenopathy 31 frequent (33%) HP:0002716
18 fatigable weakness 31 frequent (33%) HP:0003473
19 decreased antibody level in blood 31 occasional (7.5%) HP:0004313
20 interstitial pulmonary abnormality 31 frequent (33%) HP:0006530
21 b lymphocytopenia 31 occasional (7.5%) HP:0010976
22 fatigue 31 frequent (33%) HP:0012378
23 cough 31 frequent (33%) HP:0012735
24 myocarditis 31 occasional (7.5%) HP:0012819
25 abnormality of the mediastinum 31 hallmark (90%) HP:0045026
26 neoplasm of the thymus 31 hallmark (90%) HP:0100521
27 myositis 31 occasional (7.5%) HP:0100614
28 thyroiditis 31 occasional (7.5%) HP:0100646
29 chest pain 31 frequent (33%) HP:0100749

GenomeRNAi Phenotypes related to Thymoma according to GeneCards Suite gene sharing:

25 (show all 45)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 10.46 LCK KIT AKT2 AKT1 AKT3
2 Decreased viability GR00221-A-2 10.46 LCK AKT1 AKT3
3 Decreased viability GR00221-A-3 10.46 LCK AKT2 AKT1 AKT3
4 Decreased viability GR00221-A-4 10.46 AKT2 AKT1 AKT3
5 Decreased viability GR00301-A 10.46 LCK KIT AKT3 AKT2
6 Decreased viability GR00342-S-1 10.46 LCK
7 Decreased viability GR00342-S-3 10.46 LCK AKT2
8 Decreased substrate adherent cell growth GR00193-A-1 10 KIT AKT2
9 Decreased substrate adherent cell growth GR00193-A-2 10 LCK KIT AKT3 AKT2
10 Decreased substrate adherent cell growth GR00193-A-3 10 LCK AKT3 AKT2
11 Decreased substrate adherent cell growth GR00193-A-4 10 LCK KIT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.91 KIT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-106 9.91 AKT3
14 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.91 AKT2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.91 AKT2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.91 AKT3
17 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.91 LCK
18 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.91 LCK
19 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.91 KIT
20 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.91 KIT
21 Increased shRNA abundance (Z-score > 2) GR00366-A-159 9.91 AKT2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.91 AKT1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.91 AIRE
24 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.91 AKT3
25 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.91 KIT
26 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.91 AKT1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.91 AIRE
28 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.91 LCK
29 Increased shRNA abundance (Z-score > 2) GR00366-A-2 9.91 LCK
30 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.91 LCK
31 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.91 LCK
32 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.91 KIT
33 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.91 AKT2
34 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.91 AKT3
35 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.91 KIT AKT1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.91 AIRE
37 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.91 AKT1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.91 AKT3
39 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.91 AKT1
40 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.91 AKT1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-80 9.91 AIRE
42 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.91 KIT LCK AIRE AKT1 AKT3 AKT2
43 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.91 KIT
44 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.91 KIT
45 Increased cell viability after pRB stimulation GR00230-A-1 9.35 LCK KIT AKT1 AKT3 AKT2

MGI Mouse Phenotypes related to Thymoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.18 TTN KIT NKX2-1 PTPRC RYR1 IL2
2 hematopoietic system MP:0005397 10.17 KIT LCK PTPRC AKT3 AIRE CD5
3 endocrine/exocrine gland MP:0005379 10.16 KIT LCK NKX2-1 PTPRC AKT3 AIRE
4 immune system MP:0005387 10.15 KIT TTN LCK PTPRC AKT3 AIRE
5 liver/biliary system MP:0005370 9.87 KIT PTPRC AIRE CTLA4 AKT1 AKT2
6 neoplasm MP:0002006 9.86 NKX2-1 PTPRC KIT AKT3 AIRE AKT1
7 normal MP:0002873 9.8 TTN NKX2-1 PPL PTPRC KIT THY1
8 no phenotypic analysis MP:0003012 9.7 KIT NKX2-1 PTPRC IL2 AIRE CD5
9 respiratory system MP:0005388 9.32 THY1 NKX2-1 PTPRC RYR1 KIT AIRE

Drugs & Therapeutics for Thymoma

Drugs for Thymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 130)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azathioprine Approved Phase 4 446-86-6 2265
2
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
3 Immunosuppressive Agents Phase 4,Phase 2,Phase 1
4 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
5 Antimetabolites Phase 4
6 Antimetabolites, Antineoplastic Phase 4
7 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
8 Antirheumatic Agents Phase 4,Phase 1,Phase 2
9 glucocorticoids Phase 4,Phase 3,Phase 2
10 Hormone Antagonists Phase 4,Phase 3,Phase 2
11 Hormones Phase 4,Phase 3,Phase 2
12 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
13
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
15
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
16
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
17
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
18 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
19 Liver Extracts Phase 3,Phase 1,Phase 2
20 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
21 Etoposide phosphate Phase 3,Phase 2,Phase 1
22 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
23 Adjuvants, Anesthesia Phase 3
24 Analgesics Phase 3,Phase 1,Phase 2
25 Analgesics, Opioid Phase 3
26 Anesthetics Phase 3
27 Anesthetics, General Phase 3
28 Anesthetics, Intravenous Phase 3
29 Central Nervous System Depressants Phase 3
30 Narcotics Phase 3
31 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
32 Methylprednisolone acetate Phase 3,Phase 2
33 Methylprednisolone Hemisuccinate Phase 3,Phase 2
34 Prednisolone acetate Phase 3,Phase 2
35 Prednisolone hemisuccinate Phase 3,Phase 2
36 Prednisolone phosphate Phase 3,Phase 2
37 Cola Nutraceutical Phase 3,Phase 2,Phase 1
38
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 38904 498142
39
Melphalan Approved Phase 2 148-82-3 460612 4053
40
Octreotide Approved, Investigational Phase 2 83150-76-9 6400441 383414
41
Bevacizumab Approved, Investigational Phase 2 216974-75-3
42
Belinostat Approved, Investigational Phase 2,Phase 1 866323-14-0
43
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
44
Pemetrexed Approved, Investigational Phase 2,Phase 1 150399-23-8, 137281-23-3 60843 446556
45
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
46
Busulfan Approved, Investigational Phase 2 55-98-1 2478
47
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
48
Somatostatin Approved, Investigational Phase 2 38916-34-6, 51110-01-1 53481605
49
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
50
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177

Interventional clinical trials:

(show top 50) (show all 91)

# Name Status NCT ID Phase Drugs
1 Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis Completed NCT00987116 Phase 4 Prednisone - Azathioprine
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy Completed NCT00294658 Phase 3 prednisone alone
4 Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma Recruiting NCT02014805 Phase 3
5 Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma Recruiting NCT02633514 Phase 3 Cisplatin;Etoposide
6 Preoperative Treatment of Patients With High Risk Thymoma Completed NCT00387868 Phase 2 cisplatin and etoposide
7 Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy Completed NCT00965250 Phase 2 IMC-12
8 Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size Completed NCT02021942 Phase 2 SOM230 LAR
9 A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer Completed NCT00369889 Phase 2 bevacizumab;Erlotinib
10 Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma Completed NCT00003283 Phase 2 octreotide acetate;prednisone
11 Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma Completed NCT00332969 Phase 2 Octreotide
12 Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage Completed NCT00589290 Phase 2 Belinostat (PDX101)
13 Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma Completed NCT00010257 Phase 2 carboplatin;paclitaxel
14 Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00198133 Phase 2 Premetrexed (Alimta)
15 Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer Completed NCT00024076 Phase 2
16 Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT01369849 Phase 1, Phase 2 Akt Inhibitor MK2206;Bendamustine Hydrochloride
17 Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions Completed NCT00003336 Phase 2 busulfan;cyclophosphamide;melphalan;methylprednisolone
18 High Dose Somatostatin Analogues in Neuroendocrine Tumors Completed NCT00990535 Phase 2 Octreotide-LAR
19 Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases Completed NCT00003662 Phase 2 busulfan;cyclophosphamide;cyclosporine;melphalan;methylprednisolone
20 Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer Completed NCT01312324 Phase 2 neoadjuvant docetaxel/cisplatin
21 Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity Completed NCT01163552 Phase 2
22 Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer Completed NCT00054132 Phase 2 Erlotinib Hydrochloride
23 Study of Chemoradiotherapy for Inoperable Locally Advanced (Stage Ⅲ/Ⅳa) Thymoma or Thymic Carcinoma Recruiting NCT02636556 Phase 2
24 A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas Recruiting NCT02220855 Phase 2 BKM120
25 A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy Recruiting NCT03076554 Phase 2 Avelumab
26 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) Recruiting NCT03449173 Phase 2 Sunitinib
27 Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases Recruiting NCT02859415 Phase 1, Phase 2 Mithramycin
28 Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin Recruiting NCT02535312 Phase 1, Phase 2 Cisplatin;Methoxyamine;Pemetrexed Disodium
29 CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis Recruiting NCT02629419 Phase 2 Amphotericin B
30 Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2 Pembrolizumab
31 Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Recruiting NCT01306045 Phase 2 AZD6244;MK-2206;Lapatinib;Erlotinib;Sunitinib
32 Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Active, not recruiting NCT02049047 Phase 2 Everolimus
33 Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy Active, not recruiting NCT01301391 Phase 2 Milciclib Maleate
34 Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma Active, not recruiting NCT01025089 Phase 2 Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
35 Sunitinib for Advanced Thymus Cancer Following Earlier Treatment Active, not recruiting NCT01621568 Phase 2 Sunitinib
36 A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Active, not recruiting NCT01364727 Phase 2 Amrubicin
37 Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma Active, not recruiting NCT01011439 Phase 2 Milciclib Maleate
38 Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma Active, not recruiting NCT02364076 Phase 2 Pembrolizumab;Epacadostat
39 Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Active, not recruiting NCT01802320 Phase 2 Akt Inhibitor MK2206
40 Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer Active, not recruiting NCT01964924 Phase 2 Akt Inhibitor GSK2141795;Trametinib
41 A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma Active, not recruiting NCT02623127 Phase 2 Sunitinib
42 Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) Not yet recruiting NCT03134118 Phase 2 Nivolumab
43 Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy Not yet recruiting NCT03193437 Phase 2 Open Label Selinexor
44 K-BASKET, TAS-117, PI3K/AKT Gene Aberration Not yet recruiting NCT03017521 Phase 2 TAS-117
45 A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor Not yet recruiting NCT03219554 Phase 2 Palbociclib
46 A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor Not yet recruiting NCT02607631 Phase 2 Pembrolizumab
47 Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum Suspended NCT02054104 Phase 1, Phase 2 Cyclophosphamide;Celecoxib
48 Paclitaxel and Cisplatin for Thymic Neoplasm Terminated NCT00818090 Phase 2 paclitaxel and cisplatin
49 Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer Terminated NCT00718809 Phase 2 saracatinib
50 A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies Terminated NCT01100944 Phase 1, Phase 2 PXD101with cisplatin+doxorubicin+cyclophosphamide

Search NIH Clinical Center for Thymoma

Cochrane evidence based reviews: thymoma

Genetic Tests for Thymoma

Anatomical Context for Thymoma

The Foundational Model of Anatomy Ontology organs/tissues related to Thymoma:

18
The Thymus

MalaCards organs/tissues related to Thymoma:

38
Thymus, Lung, T Cells, Thyroid, Testes, Skin, Liver

Publications for Thymoma

Articles related to Thymoma:

(show top 50) (show all 1086)
# Title Authors Year
1
MSA Mimic? Rare Occurrence of Anti-Hu Autonomic Failure and Thymoma in a Patient with Parkinsonism: Case Report and Literature Review. ( 29416500 )
2018
2
Assessment of Lymphoid Molecular Clonality in Canine Thymoma. ( 29422318 )
2018
3
Abscopal effects of radiotherapy and combined mRNA-based immunotherapy in a syngeneic, OVA-expressing thymoma mouse model. ( 29335856 )
2018
4
Thymoma-associated multiorgan autoimmunity with exclusive gastrointestinal tract involvement: case report and review of the literature. ( 29374317 )
2018
5
Dosimetric benefit of adaptive radiotherapy in the neoadjuvant management of canine and feline thymoma-An exploratory case series. ( 29316134 )
2018
6
Rapidly progressive subacute motor neuronopathy disclosing type B2 thymoma. ( 29364399 )
2018
7
Core Needle Biopsy of an Anterior Mediastinal Thymoma: Creation of a Safe Access Route by Hydrodissection. ( 29373145 )
2018
8
Acquired amegakaryocytic thrombocytopenia and red cell aplasia in a patient with thymoma progressing to aplastic anemia successfully treated with allogenic stem cell transplantation. ( 29409729 )
2018
9
Thymoma-associated myasthenia gravis and LGI1-encephalitis, with nephrotic syndrome post-thymectomy. ( 29395322 )
2018
10
Video-assisted thoracoscopic thymectomy for thymoma: a single-center experience. ( 29411632 )
2018
11
Wnt4 overexpression promotes thymoma development through a JNK-mediated planar cell polarity-like pathway. ( 29387212 )
2018
12
Predicted Rate of Secondary Malignancies Following Adjuvant Proton Versus Photon Radiation Therapy for Thymoma. ( 28871993 )
2017
13
Clinical and pathological aspects of microscopic thymoma with myasthenia gravis and review of published reports. ( 28740673 )
2017
14
Stage-II thymoma and emergency coronary artery bypass. To irradiate or not to irradiate to avoid radiation induced vascular injury? Case report and literature review. ( 29332327 )
2017
15
"Minimalist" resection for thymoma: Is less really more? ( 28784241 )
2017
16
Different neurologic outcomes of myasthenia gravis with thymic hyperplasia and thymoma after extended thymectomy: A single center experience. ( 29246632 )
2017
17
Thymoma-associated multi-organ autoimmunity: A case of graft-versus-host disease-like erythroderma complicated by Good syndrome successfully treated by thymectomy. ( 28256733 )
2017
18
Pathological Findings in Myasthenia Gravis Patients with Thymic Hyperplasia and Thymoma. ( 28299711 )
2017
19
Ectopic Hamartomatous Thymoma: A Review Of The Literature With Report Of New Cases And Proposal Of A New Name: Biphenotypic Branchioma. ( 28879635 )
2017
20
Role of Postoperative Radiation Therapy inA Completely Resected Thymoma. ( 28007247 )
2017
21
VATS thymectomy for early stage thymoma and myasthenia gravis: combined right-sided uniportal and left-sided three-portal approach. ( 29302420 )
2017
22
Peritoneal recurrence of thymoma treated by surgery and hyperthermic intraperitoneal chemotherapy. ( 28838398 )
2017
23
D2-40 Antibody is a Specific Marker for B2 Thymomas. ( 26808132 )
2017
24
Thymoma-associated immunodeficiency: a diagnostic challenge for the clinician. ( 28068785 )
2017
25
Ectopic thymoma managed by neck dissection & video-assisted thoracoscopic thymectomy. ( 29312764 )
2017
26
Cyclosporin A Reversed Chemoresistance of a Patient with Pure Red Cell Aplasia Secondary to Thymoma. ( 28739760 )
2017
27
Ectopic Cervical Thymoma: A Case Report and Review. ( 28795042 )
2017
28
Thymoma with immunodeficiency/Good syndrome associated with myasthenia gravis. ( 28450687 )
2017
29
A Case of Paraneoplastic Limbic Encephalitis in a Patient with Invasive Thymoma with Anti-Glutamate Receptor Antibody-Positive Cerebrospinal Fluid: A Case Report. ( 29269707 )
2017
30
Thymoma-associated multi-organ autoimmunity: two cases and a review of the literature. ( 28052464 )
2017
31
Seronegative Paraneoplastic Limbic Encephalitis Associated with Thymoma. ( 28926420 )
2017
32
Sclerosing thymoma-like thymic amyloidoma with nephrotic syndrome: a case report. ( 28877738 )
2017
33
Maxillary Sinus Kaposi Sarcoma: Case Report in an HIV-Negative Patient with Thymoma. ( 29204303 )
2017
34
Polyparaneoplastic Manifestations of Malignant Thymoma: A Unique Case of Myasthenia, Autoimmune Hepatitis, Pure Red Cell Aplasia, and Keratoconjunctivitis Sicca. ( 28744421 )
2017
35
Correction: Long term oncological outcome of thymoma and thymic carcinoma - an analysis of 235 cases from a single institution. ( 28931090 )
2017
36
GVHD-like erythroderma in the clinical course of thymoma-associated myasthenia gravis. ( 28524043 )
2017
37
Uniportal video-assisted thoracoscopic thymectomy and resection of a giant thymoma in a patient witness of Jehova. ( 28740696 )
2017
38
Secondary systemic lupus erythematosus after thymoma resection misdiagnosed as medically unexplained dyspnoea: A case report. ( 29310389 )
2017
39
Pure red cell aplasia and myasthenia gravis: a patient having both autoimmune conditions in the absence of thymoma. ( 28893803 )
2017
40
Fetal sequential multiorgan autoimmunity associated with recurrent post thymectomy thymoma. ( 28778703 )
2017
41
THYMOMA: A clinicopathological correlation of 1470 cases. ( 28851660 )
2017
42
Robotic thymectomy for myasthenia gravis with or without thymoma-surgical and neurological outcomes. ( 28084239 )
2017
43
Robotic trans-subxiphoid extended thymectomy in a patient with thymoma-associated pemphigus. ( 28740698 )
2017
44
Nephrotic syndrome associated with metastatic thymoma treated with chemotherapy. ( 28072685 )
2017
45
A rare case of thymoma first detected on gallium-68 PSMA PET/CT. ( 28765999 )
2017
46
Postoperative Radiotherapy in Completely Resected Stage II and III Thymoma: How to Translate the Potential Survival Benefit inA the Setting of the FutureA Adoption of the IASLC-ITMIG TNM-Based Staging System. ( 27988104 )
2017
47
Propensity Score Adjusted Comparison of Minimally Invasive versus Open Thymectomy in the Management of Early Stage Thymoma. ( 28806823 )
2017
48
Micronodular thymoma with lymphoid stroma: Two cases, one in a multilocular thymic cyst, and literature review. ( 28941195 )
2017
49
Could thymomectomy be a reasonable option for non-myasthenic thymoma patients? ( 29268390 )
2017
50
Corrigendum to 'High rate of unnecessary thymectomy and its cause. Can computed tomography distinguish thymoma, lymphoma, thymic hyperplasia, and thymic cysts?' [EURR 84 (3) (2015) 524-533]. ( 28238381 )
2017

Variations for Thymoma

ClinVar genetic disease variations for Thymoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 KIT NM_000222.2(KIT): c.1676T> C (p.Val559Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913517 GRCh37 Chromosome 4, 55593610: 55593610
2 HRAS NM_005343.3(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 GRCh38 Chromosome 11, 534285: 534285
3 KIT NM_000222.2(KIT): c.2460T> A (p.Asp820Glu) single nucleotide variant Pathogenic rs1057519711 GRCh37 Chromosome 4, 55599334: 55599334
4 KIT NM_000222.2(KIT): c.1468G> A (p.Glu490Lys) single nucleotide variant Pathogenic rs1057519701 GRCh37 Chromosome 4, 55592144: 55592144
5 KIT NM_000222.2(KIT): c.1657T> A (p.Tyr553Asn) single nucleotide variant Pathogenic rs1057519704 GRCh37 Chromosome 4, 55593591: 55593591
6 KIT NM_000222.2(KIT): c.1669T> C (p.Trp557Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913235 GRCh38 Chromosome 4, 54727437: 54727437
7 KIT NM_000222.2(KIT): c.1679_1681delTTG (p.Val560del) deletion Pathogenic/Likely pathogenic rs121913685 GRCh37 Chromosome 4, 55593612: 55593614
8 KIT NM_000222.2(KIT): c.1727T> C (p.Leu576Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913513 GRCh37 Chromosome 4, 55593661: 55593661
9 KIT NM_000222.2(KIT): c.1730_1738delCTTATGATC (p.Pro577_Asp579del) deletion Pathogenic rs1131692239 GRCh37 Chromosome 4, 55593664: 55593672

Expression for Thymoma

Search GEO for disease gene expression data for Thymoma.

Pathways for Thymoma

Pathways related to Thymoma according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.49 AKT1 AKT2 AKT3 DPYSL5 EVPL IL2
2
Show member pathways
13.47 AKT1 AKT2 AKT3 CTLA4 KIT LCK
3
Show member pathways
13.34 AKT1 AKT2 AKT3 CD2 IL2 LCK
4
Show member pathways
13.31 AKT1 AKT2 AKT3 CD2 IL2 KIT
5
Show member pathways
13.07 AKT1 AKT2 AKT3 IL2 KIT LCK
6
Show member pathways
12.93 AKT1 AKT2 AKT3 CTLA4 LCK PTPRC
7 12.85 AKT1 AKT2 AKT3 IL2 KIT
8
Show member pathways
12.74 AKT1 AKT2 AKT3 KIT LCK
9
Show member pathways
12.62 AKT1 AKT2 AKT3 IL2 LCK PTPRC
10
Show member pathways
12.57 AKT1 AKT2 AKT3 LCK PTPRC
11
Show member pathways
12.54 AKT1 AKT2 AKT3 CTLA4 LCK
12 12.47 CD2 CTLA4 IL2 KIT LCK PTPRC
13
Show member pathways
12.45 AKT1 AKT2 AKT3 IL2
14 12.42 AKT1 AKT2 AKT3 IL2 LCK
15
Show member pathways
12.41 AKT1 AKT2 AKT3 KIT
16
Show member pathways
12.39 AKT1 AKT2 AKT3 RYR1
17
Show member pathways
12.38 AKT1 AKT2 AKT3 LCK PTPRC
18
Show member pathways
12.37 AKT1 AKT2 AKT3 IL2
19
Show member pathways
12.32 AKT1 AKT2 AKT3 PTPRC
20
Show member pathways
12.15 AKT1 AKT2 AKT3 CTLA4 LCK
21
Show member pathways
12.11 AKT1 AKT2 AKT3 CTLA4 IL2 LCK
22 12.08 AKT1 AKT2 AKT3 RYR1
23
Show member pathways
12.07 AKT1 AKT2 AKT3 IL2 LCK
24 12.04 AKT1 AKT2 AKT3 LCK
25
Show member pathways
12.04 AKT1 AKT2 AKT3 IL2 LCK
26
Show member pathways
12.02 AKT1 AKT2 AKT3 IL2
27 11.92 AKT1 AKT2 AKT3
28
Show member pathways
11.92 AKT1 AKT2 AKT3
29 11.91 AKT1 AKT2 AKT3
30 11.9 KIT PTPRC THY1
31 11.89 AKT1 AKT2 AKT3
32 11.89 CD2 CD5 DNTT KIT
33 11.88 AKT1 AKT2 AKT3
34
Show member pathways
11.88 AKT1 AKT2 AKT3 CTLA4 IL2 LCK
35 11.87 AKT1 AKT2 AKT3
36 11.86 AKT1 AKT2 AKT3
37 11.85 AKT1 AKT2 AKT3 PTPRC
38
Show member pathways
11.83 AKT1 AKT2 AKT3
39 11.83 AKT1 AKT2 AKT3
40
Show member pathways
11.8 AKT1 AKT2 AKT3 IL2
41
Show member pathways
11.79 AKT1 AKT2 AKT3 KIT
42
Show member pathways
11.79 AKT1 AKT2 AKT3 IL2 LCK
43 11.77 AKT1 LCK PTPRC
44 11.76 IL2 KIT PTPRC THY1
45 11.75 AKT1 AKT2 AKT3
46
Show member pathways
11.75 AKT1 AKT2 AKT3
47 11.72 AKT1 AKT2 AKT3
48 11.72 IL2 KIT PTPRC THY1
49 11.71 AKT1 AKT2 AKT3 LCK
50 11.71 AKT1 AKT2 AKT3 IL2 PTPRC

GO Terms for Thymoma

Cellular components related to Thymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.1 CD2 CD5 CTLA4 KIT PTPRC THY1

Biological processes related to Thymoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 9.88 AKT1 AKT2 AKT3 KIT LCK TTN
2 protein phosphorylation GO:0006468 9.8 AKT1 AKT2 AKT3 KIT LCK TTN
3 B cell receptor signaling pathway GO:0050853 9.67 CTLA4 LCK PTPRC
4 regulation of cell migration GO:0030334 9.65 AKT1 AKT2 THY1
5 positive regulation of glycogen biosynthetic process GO:0045725 9.54 AKT1 AKT2
6 regulation of regulatory T cell differentiation GO:0045589 9.52 CTLA4 IL2
7 mammary gland epithelial cell differentiation GO:0060644 9.51 AKT1 AKT2
8 positive regulation of mitochondrial membrane potential GO:0010918 9.46 AKT1 AKT2
9 positive regulation of glucose metabolic process GO:0010907 9.43 AKT1 AKT2
10 peripheral nervous system myelin maintenance GO:0032287 9.37 AKT1 AKT2
11 release of sequestered calcium ion into cytosol GO:0051209 9.33 LCK PTPRC RYR1
12 negative regulation of plasma membrane long-chain fatty acid transport GO:0010748 9.26 AKT1 AKT2
13 T cell costimulation GO:0031295 9.26 AKT1 CD5 CTLA4 LCK
14 T cell differentiation GO:0030217 8.92 IL2 KIT LCK PTPRC

Molecular functions related to Thymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 AIRE AKT1 AKT2 AKT3 CD2 CD5
2 kinase activity GO:0016301 9.73 AKT1 AKT2 AKT3 KIT LCK TTN
3 protein kinase binding GO:0019901 9.72 AKT1 LCK PTPRC THY1 TTN
4 enzyme binding GO:0019899 9.55 AKT1 NKX2-1 RYR1 THY1 TTN
5 protein kinase activity GO:0004672 9.1 AKT1 AKT2 AKT3 KIT LCK TTN

Sources for Thymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....